Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
Details
The document's own metadata, straight from the source system.
- Title
- Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
- Posted
- May 22, 2026
- Comment period
- May 22, 2026 – Jun 18, 2026
- FR Doc
- 2026-10321
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Choose up to five.
| Organization | Vaccine updates and accessibility |
|---|
1 organization-typed comment could not be identified.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jun 5, 2026Comment from AnonymousOtherIndividual
The commenter provides a critique of the disclosure process for a scientific publication, arguing that administrative errors in conflict-of-interest forms undermine scientific confidence. The comment focuses on the systemic failures of journal editorial oversight rather than taking a specific position on the safety or effectiveness of the MFLUSIVA vaccine.
Read comment → - May 26, 2026Comment from AnonymousSupportIndividualRead comment →